theorized that this was due to the extended half life of anti PD 1 drugs, whereby the reintroduction with anti CTLA 4 monotherapy following anti PD 1 liver toxicity can create a scenario as if the patient was receiving combination therapy 121

مهمان عزیز شما حق دیدن لینک ها را ندارید برای استفاده از امکانات کامل انجمن عضو شوید

عضویت